10X Genomics, Inc. (TXG)
| Market Cap | 15.92B |
| Revenue (ttm) | 298.85M |
| Net Income (ttm) | -542.73M |
| Shares Out | 101.15M |
| EPS (ttm) | -5.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $146.36 |
| Previous Close | $144.45 |
| Change ($) | 1.91 |
| Change (%) | 1.32% |
| Day's Open | 147.18 |
| Day's Range | 145.76 - 151.83 |
| Day's Volume | 1,090,529 |
| 52-Week Range | 72.04 - 203.25 |
The company delivered tremendous revenue growth but a deteriorating bottom line.
10x Genomics (TXG) delivered earnings and revenue surprises of 56.00% and 2.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Q1 2021 revenue growth of 47% over prior year Q1 2021 revenue growth of 47% over prior year
On Wednesday, May 05, 10x Genomics (NASDAQ:TXG) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
PLEASANTON, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Confere...
How much potential does this company have?
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.
Here's why she likes them so much.
PLEASANTON, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5th, 20...
The company's technology is helping researchers understand the genetic underpinnings of the disease.
The company's technology is enabling researchers to explore single cells like never before.
The company's genomics technology was important in the research of these two diseases.
10x Genomics CEO Serge Saxonov thinks we're at the threshold of some big discoveries.
The company's CEO thinks it's capitalizing on the biggest value-creation opportunity of the next several decades.
10x Genomics' CEO identifies three key things to look for.
Several trends are converging.
The bottom line: Vaccines are working.
Along with recent release of CellPlex, product increases access through affordability Along with recent release of CellPlex, product increases access through affordability
Eighteen months after going public, 10x Genomics Inc.'s (TGX) shares have tripled to more than $166, yet analysts think that's still well below its twelve-month median price target. Some on Wall Street ...
City to Change Street Name to ‘Genomics Place'
CHICAGO--(BUSINESS WIRE)--OMX Ventures expands team with addition of Jamie Kasuboski, Ph.D. as Vice President and Kevin Ness, Ph.D. as Fund Advisor.
2020 was a year that will be hard to forget. The headlines were dominated by the pandemic and its social and economic aftermath, but there were also wildfires, violent social and racial unrest, the U.S....
PLEASANTON, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference.
Acquires Tetramer Shop; Reveals Details on Upcoming Products Acquires Tetramer Shop; Reveals Details on Upcoming Products
The problem was the company's worsening bottom line.
Q4 2020 revenue growth of 49% over prior year
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after marke...
10X Genomics Strategy Driven By Innovation, CEO Says
Jan.12 -- 10X Genomics Inc. Chief Executive Officer Serge Saxonov discusses the company's strategy and performance amid the Covid-19 pandemic with Bloomberg's Vonnie Quinn on "Bloomberg Markets."
PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.
10X Genomics is a cutting edge, single-cell assay hardware, software and consumables company. Don't feel bad, I don't understand all of that either.
Here's how these big businesses became enormous during a year most of us would rather forget.
10X Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Earnings Call Transcript
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Quick Version Earnings Call Transcript
10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.
PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2...
10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.
Covid-19 Vaccine Likely Early 2021, Says 10x Genomics CEO
Oct.07 -- Serge Saxonov, co-founder and chief executive officer at 10x Genomics Inc., discusses developments on a vaccine for Covid-19 on "Bloomberg Technology."
Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB
10x Genomics, Inc. has performed outstandingly well since the COVID-19 induced lows of March, more than doubling in this time.
PLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A common sto...
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Cla...
PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shar...
These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me... [Read more...]
| Industry Health Information Services | IPO Date Sep 12, 2019 |
| CEO Serge Saxonov | Employees 852 |
| Stock Exchange NASDAQ | Ticker Symbol TXG |
Financial Performance
In 2020, 10X Genomics's revenue was $298.85 million, an increase of 21.53% compared to the previous year's $245.89 million. Losses were -$542.73 million, 1,636.7% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for 10X Genomics stock is "Buy." The 12-month stock price forecast is 209.57, which is an increase of 43.19% from the latest price.